Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Katsuki Iwamoto"'
Autor:
Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Yuichi Machida, Tetsuji Ohmachi, Keiichi Ishii, Hiroyuki Iwata, Shinji Yamamoto, Tomohiro Kanamaru, Kazuya Morimoto, Taro Hase, Koichiro Tashiro, Koji Harimoto, Takashi Deguchi, Takahisa Adachi, Katsuki Iwamoto, Yoshinori Takegaki, Tatsuya Nakatani
Publikováno v:
International journal of clinical oncology. 25(3)
Before the androgen target therapy era, flutamide was widely used for castration-resistant prostate cancer in Japan. Enzalutamide is currently the recommended treatment; however, the efficacy and safety of enzalutamide and flutamide after combined an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c507460b3e95d353b2f0e86662ff005
https://pubmed.ncbi.nlm.nih.gov/31564004
https://pubmed.ncbi.nlm.nih.gov/31564004
Autor:
Taro Hase, Hiroyuki Iwata, Takashi Deguchi, Katsuki Iwamoto, Kazuya Morimoto, Takahisa Adachi, Satoshi Tamada, Minoru Kato, Tatsuya Nakatani, Taiyo Otoshi, Keiichi Ishii, Yoshinori Takegaki, Tetsuji Ohmachi, Koji Harimoto, Sayaka Yasuda, Tomohiro Kanamaru, Taro Iguchi, Koichiro Tashiro, Y. Machida, Shinji Yamamoto
Publikováno v:
Journal of Clinical Oncology. 37:5042-5042
5042 Background: In Asia, bicalutamide-combined androgen blockade (CAB) is widely used to treat metastatic or locally advanced prostate cancer. Enzalutamide (ENZA) shows benefits in men with metastatic and nonmetastatic castration-resistant prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ff1fd1e44744cd3923386bd533f71eb
https://doi.org/10.1200/jco.2019.37.15_suppl.5042
https://doi.org/10.1200/jco.2019.37.15_suppl.5042
Autor:
Y. Machida, Koji Harimoto, Sayaka Yasuda, Taro Hase, Taro Iguchi, Koichiro Tashiroro, Tetsuji Ohmachi, Yoshinori Takegaki, Hiroyuki Iwata, Tomohiro Kanamaru, Takahisa Adachi, Kazuya Morimoto, Katsuki Iwamoto, Tatsuya Nakatani, Satoshi Tamada, Minoru Kato, Keiichi Ishii, Shinji Yamamoto, Takashi Deguhi
Publikováno v:
Journal of Clinical Oncology. 37:168-168
168 Background: In Asia, including Japan, combined androgen blockade (CAB) therapy with bicalutamide is widely administered for metastatic prostate cancer. Alternative anti-androgen therapy (AAT) with flutamide after CAB therapy with bicalutamide was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eef3b4aa7acc81d6b44f2d4fa0382666
https://doi.org/10.1200/jco.2019.37.7_suppl.168
https://doi.org/10.1200/jco.2019.37.7_suppl.168